Contraception
Volume 81, Issue 1 , Pages 35-40, January 2010

Oral contraceptive use and bone density in adolescent and young adult women

  • Delia Scholes

      Affiliations

    • Group Health Center for Health Studies, Group Health Cooperative, Seattle, WA 98101, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 206 287 2888; fax: +1 206 287 2871.
  • ,
  • Laura Ichikawa

      Affiliations

    • Group Health Center for Health Studies, Group Health Cooperative, Seattle, WA 98101, USA
  • ,
  • Andrea Z. LaCroix

      Affiliations

    • Group Health Center for Health Studies, Group Health Cooperative, Seattle, WA 98101, USA
    • Women's Health Initiative, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
  • ,
  • Leslie Spangler

      Affiliations

    • Group Health Center for Health Studies, Group Health Cooperative, Seattle, WA 98101, USA
  • ,
  • Jeannette M. Beasley

      Affiliations

    • Group Health Center for Health Studies, Group Health Cooperative, Seattle, WA 98101, USA
    • Women's Health Initiative, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
  • ,
  • Susan Reed

      Affiliations

    • Group Health Center for Health Studies, Group Health Cooperative, Seattle, WA 98101, USA
    • Department of Obstetrics and Gynecology, University of Washington, Seattle, WA 98195, USA
  • ,
  • Susan M. Ott

      Affiliations

    • Department of Medicine, University of Washington, Seattle, WA 98195, USA

Received 23 May 2009; received in revised form 4 July 2009; accepted 7 July 2009. published online 25 August 2009.

Abstract 

Background

Most of the millions of oral contraceptive (OC) users are under 30 years of age and in the critical period for bone mass accrual.

Study Design

This cross-sectional study of 606 women aged 14–30 years examined both OC duration and estrogen dose and their association with bone mineral density (BMD) at the hip, spine, and whole body (dual-energy X-ray absorptiometry).

Results

Of 389 OC users and 217 nonusers enrolled, 50% were adolescents (14–18 years). Of OC users, 38% used “low-dose” OCs [<30 mcg ethinyl estradiol (EE)]. In adolescents, mean BMD differed by neither OC duration nor EE dose. However, 19- to 30-year-old women's mean BMD was lower with longer OC use for spine and whole body (p=.004 and p=.02, respectively) and lowest for >12 months of low-dose OCs for the hip, spine and whole body (p=.02, .003 and .002, respectively).

Conclusions

Prolonged use of today's OCs, particularly <30 mcg EE, may adversely impact young adult women's bone density while using these agents.

Keywords: Bone mineral density, Oral contraceptives, Hormones, Peak bone density, Adolescents

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 This study was funded by grant 1R01-HD31165-11 (Scholes) from the National Institute for Child Health and Human Development, National Institutes of Health. Dr. Beasley is a postdoctoral fellow supported by T-32 AG027677 from the National Institute on Aging.

PII: S0010-7824(09)00346-1

doi:10.1016/j.contraception.2009.07.001

Contraception
Volume 81, Issue 1 , Pages 35-40, January 2010